Critical
Moxifloxacin × Sotalol
Fourth-generation fluoroquinolone×Non-selective beta blocker with class III antiarrhythmic activity
Mechanism
Dual QT prolongation. Torsades de pointes.
Symptoms
QTc above 500 ms, syncope, torsades de pointes risk.
Management
Combination contraindicated.
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Sources
- FDA: Avelox (moxifloxacin) prescribing information – QT prolongation warning (2016)– FDA Avelox label, Warnings and Precautions §5.7 – avoid with QT-prolonging drugs
- FDA: Betapace (sotalol) prescribing information – QT and antiarrhythmic interactions (2011)– FDA Betapace label, Contraindications §4 and Warnings §5
- FDA: Betapace (sotalol) prescribing information (2011)